GenEdit Inc.
https://genedit.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From GenEdit Inc.
Finance Watch: Ascendis Spins Out Ophthalmology Firm Eyconis With $150m
Private Company Edition: Publicly held Ascendis outsourced its preclinical AMD program to private Eyconis. Also, Innovation Endeavors revealed a new $630m VC fund and Mirae raised $50m for its first life science fund, while Accent, Comanche and Tr1X each brought in $75m rounds.
Genentech Places Bet On Polymer Nanoparticle-Based Delivery With GenEdit Deal
Deal Snapshot: The Roche subsidiary will use GenEdit’s hydrophilic nanoparticles to develop genetic medicines for autoimmune diseases meant to overcome the limitations of existing delivery methods.
How KIMCo Is Orchestrating Korean Pharma Collaborations
KIMCo CEO Kevin Kyunghwa Huh talks about the consortium's efforts to become a platform of collaboration for Korean pharmas, including plans for the latest joint investment project as well as how the domestic industry is evolving in terms of globalization and open innovation.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Nanotechnology, Chips, etc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice